nodes	percent_of_prediction	percent_of_DWPC	metapath
Lovastatin—UGT2B7—Epirubicin—sarcoma	0.13	0.179	CbGbCtD
Lovastatin—UGT1A1—Etoposide—sarcoma	0.0875	0.121	CbGbCtD
Lovastatin—ABCC2—Vincristine—sarcoma	0.0581	0.0801	CbGbCtD
Lovastatin—ABCC2—Etoposide—sarcoma	0.0532	0.0734	CbGbCtD
Lovastatin—CYP3A7—Vincristine—sarcoma	0.0388	0.0535	CbGbCtD
Lovastatin—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0388	0.0535	CbGbCtD
Lovastatin—CYP3A4—Thiotepa—sarcoma	0.0384	0.0529	CbGbCtD
Lovastatin—ABCC2—Doxorubicin—sarcoma	0.0363	0.0501	CbGbCtD
Lovastatin—ABCB1—Dactinomycin—sarcoma	0.0308	0.0424	CbGbCtD
Lovastatin—CYP3A5—Vincristine—sarcoma	0.0291	0.0401	CbGbCtD
Lovastatin—ABCB1—Mitoxantrone—sarcoma	0.0275	0.0379	CbGbCtD
Lovastatin—CYP3A5—Etoposide—sarcoma	0.0267	0.0368	CbGbCtD
Lovastatin—CYP2C8—Etoposide—sarcoma	0.0256	0.0353	CbGbCtD
Lovastatin—ABCB1—Vincristine—sarcoma	0.0189	0.0261	CbGbCtD
Lovastatin—ABCB1—Etoposide—sarcoma	0.0174	0.0239	CbGbCtD
Lovastatin—CYP3A4—Mitoxantrone—sarcoma	0.0165	0.0227	CbGbCtD
Lovastatin—ABCB1—Doxorubicin—sarcoma	0.0118	0.0163	CbGbCtD
Lovastatin—CYP3A4—Vincristine—sarcoma	0.0113	0.0156	CbGbCtD
Lovastatin—CYP2D6—Doxorubicin—sarcoma	0.0112	0.0154	CbGbCtD
Lovastatin—CYP3A4—Etoposide—sarcoma	0.0104	0.0143	CbGbCtD
Lovastatin—CYP3A4—Doxorubicin—sarcoma	0.00709	0.00978	CbGbCtD
Lovastatin—ITGAL—endothelium—sarcoma	0.00686	0.0696	CbGeAlD
Lovastatin—ITGAL—mammary gland—sarcoma	0.00553	0.0561	CbGeAlD
Lovastatin—ITGAL—myometrium—sarcoma	0.00392	0.0398	CbGeAlD
Lovastatin—HDAC2—Teniposide—Etoposide—sarcoma	0.00357	1	CbGdCrCtD
Lovastatin—PON3—seminal vesicle—sarcoma	0.00347	0.0353	CbGeAlD
Lovastatin—ITGAL—hematopoietic system—sarcoma	0.00337	0.0342	CbGeAlD
Lovastatin—ITGAL—connective tissue—sarcoma	0.00324	0.0329	CbGeAlD
Lovastatin—ITGAL—lymphoid tissue—sarcoma	0.00237	0.0241	CbGeAlD
Lovastatin—ITGAL—tendon—sarcoma	0.00223	0.0226	CbGeAlD
Lovastatin—HDAC2—mammary gland—sarcoma	0.00221	0.0224	CbGeAlD
Lovastatin—PON3—tendon—sarcoma	0.00219	0.0222	CbGeAlD
Lovastatin—ITGAL—bone marrow—sarcoma	0.00216	0.0219	CbGeAlD
Lovastatin—PON3—bone marrow—sarcoma	0.00212	0.0215	CbGeAlD
Lovastatin—SLCO1B1—mammary gland—sarcoma	0.00191	0.0194	CbGeAlD
Lovastatin—ITGAL—testis—sarcoma	0.00185	0.0187	CbGeAlD
Lovastatin—PON3—testis—sarcoma	0.00181	0.0184	CbGeAlD
Lovastatin—ITGAL—liver—sarcoma	0.00174	0.0177	CbGeAlD
Lovastatin—PON3—liver—sarcoma	0.00171	0.0174	CbGeAlD
Lovastatin—HDAC2—embryo—sarcoma	0.00151	0.0153	CbGeAlD
Lovastatin—UGT1A3—liver—sarcoma	0.00148	0.0151	CbGeAlD
Lovastatin—HMGCR—myometrium—sarcoma	0.00141	0.0144	CbGeAlD
Lovastatin—UGT1A1—hematopoietic system—sarcoma	0.0014	0.0142	CbGeAlD
Lovastatin—HDAC2—hematopoietic system—sarcoma	0.00135	0.0137	CbGeAlD
Lovastatin—ITGAL—lymph node—sarcoma	0.00134	0.0136	CbGeAlD
Lovastatin—HDAC2—connective tissue—sarcoma	0.0013	0.0132	CbGeAlD
Lovastatin—HMGCR—seminal vesicle—sarcoma	0.00128	0.013	CbGeAlD
Lovastatin—HMGCR—hematopoietic system—sarcoma	0.00121	0.0123	CbGeAlD
Lovastatin—HDAC2—smooth muscle tissue—sarcoma	0.00119	0.012	CbGeAlD
Lovastatin—HDAC2—skin of body—sarcoma	0.00117	0.0119	CbGeAlD
Lovastatin—HMGCR—connective tissue—sarcoma	0.00117	0.0119	CbGeAlD
Lovastatin—SLCO1B1—hematopoietic system—sarcoma	0.00116	0.0118	CbGeAlD
Lovastatin—CYP2C8—mammary gland—sarcoma	0.00109	0.011	CbGeAlD
Lovastatin—HMGCR—smooth muscle tissue—sarcoma	0.00107	0.0109	CbGeAlD
Lovastatin—HMGCR—skin of body—sarcoma	0.00106	0.0107	CbGeAlD
Lovastatin—HDAC2—uterus—sarcoma	0.00102	0.0103	CbGeAlD
Lovastatin—CYP2C9—mammary gland—sarcoma	0.000965	0.00979	CbGeAlD
Lovastatin—HDAC2—lymphoid tissue—sarcoma	0.000948	0.00962	CbGeAlD
Lovastatin—SLCO1A2—hematopoietic system—sarcoma	0.000947	0.00961	CbGeAlD
Lovastatin—HMGCR—cardiac atrium—sarcoma	0.000922	0.00936	CbGeAlD
Lovastatin—HMGCR—uterus—sarcoma	0.000917	0.00931	CbGeAlD
Lovastatin—UGT2B7—testis—sarcoma	0.000901	0.00915	CbGeAlD
Lovastatin—HDAC2—tendon—sarcoma	0.000891	0.00904	CbGeAlD
Lovastatin—CYP3A7—liver—sarcoma	0.000879	0.00892	CbGeAlD
Lovastatin—HDAC2—bone marrow—sarcoma	0.000863	0.00876	CbGeAlD
Lovastatin—HMGCR—lymphoid tissue—sarcoma	0.000855	0.00868	CbGeAlD
Lovastatin—UGT2B7—liver—sarcoma	0.000852	0.00865	CbGeAlD
Lovastatin—HMGCR—tendon—sarcoma	0.000804	0.00816	CbGeAlD
Lovastatin—HMGCR—bone marrow—sarcoma	0.000779	0.0079	CbGeAlD
Lovastatin—CYP2C19—hematopoietic system—sarcoma	0.000758	0.00769	CbGeAlD
Lovastatin—CYP3A7-CYP3A51P—liver—sarcoma	0.000747	0.00759	CbGeAlD
Lovastatin—HDAC2—testis—sarcoma	0.000738	0.00749	CbGeAlD
Lovastatin—UGT1A1—liver—sarcoma	0.000724	0.00735	CbGeAlD
Lovastatin—HDAC2—liver—sarcoma	0.000697	0.00708	CbGeAlD
Lovastatin—HMGCR—testis—sarcoma	0.000666	0.00676	CbGeAlD
Lovastatin—CYP2C8—hematopoietic system—sarcoma	0.000662	0.00672	CbGeAlD
Lovastatin—HMGCR—liver—sarcoma	0.000629	0.00639	CbGeAlD
Lovastatin—SLCO1B1—liver—sarcoma	0.000603	0.00612	CbGeAlD
Lovastatin—CYP3A5—hematopoietic system—sarcoma	0.000597	0.00606	CbGeAlD
Lovastatin—CYP2C9—hematopoietic system—sarcoma	0.000588	0.00597	CbGeAlD
Lovastatin—ABCC2—tendon—sarcoma	0.000584	0.00593	CbGeAlD
Lovastatin—HDAC2—lymph node—sarcoma	0.000535	0.00543	CbGeAlD
Lovastatin—SLCO1A2—testis—sarcoma	0.000519	0.00527	CbGeAlD
Lovastatin—SLCO1A2—liver—sarcoma	0.000491	0.00498	CbGeAlD
Lovastatin—ABCC2—testis—sarcoma	0.000483	0.00491	CbGeAlD
Lovastatin—HMGCR—lymph node—sarcoma	0.000482	0.0049	CbGeAlD
Lovastatin—ABCC2—liver—sarcoma	0.000457	0.00464	CbGeAlD
Lovastatin—CYP3A4—hematopoietic system—sarcoma	0.000448	0.00455	CbGeAlD
Lovastatin—CYP2D6—hematopoietic system—sarcoma	0.000441	0.00448	CbGeAlD
Lovastatin—CYP2C19—liver—sarcoma	0.000393	0.00399	CbGeAlD
Lovastatin—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000393	0.00346	CcSEcCtD
Lovastatin—Arthralgia—Mitoxantrone—sarcoma	0.000391	0.00344	CcSEcCtD
Lovastatin—Myalgia—Mitoxantrone—sarcoma	0.000391	0.00344	CcSEcCtD
Lovastatin—Chest pain—Mitoxantrone—sarcoma	0.000391	0.00344	CcSEcCtD
Lovastatin—Paraesthesia—Thiotepa—sarcoma	0.00039	0.00343	CcSEcCtD
Lovastatin—Anxiety—Mitoxantrone—sarcoma	0.00039	0.00343	CcSEcCtD
Lovastatin—Alopecia—Etoposide—sarcoma	0.000388	0.00341	CcSEcCtD
Lovastatin—Discomfort—Mitoxantrone—sarcoma	0.000386	0.0034	CcSEcCtD
Lovastatin—Anaphylactic shock—Vincristine—sarcoma	0.000385	0.00339	CcSEcCtD
Lovastatin—Infection—Vincristine—sarcoma	0.000383	0.00337	CcSEcCtD
Lovastatin—Dyspepsia—Thiotepa—sarcoma	0.000382	0.00336	CcSEcCtD
Lovastatin—Blood alkaline phosphatase increased—Doxorubicin—sarcoma	0.000378	0.00333	CcSEcCtD
Lovastatin—Confusional state—Mitoxantrone—sarcoma	0.000378	0.00333	CcSEcCtD
Lovastatin—Decreased appetite—Thiotepa—sarcoma	0.000377	0.00332	CcSEcCtD
Lovastatin—Thrombocytopenia—Vincristine—sarcoma	0.000377	0.00332	CcSEcCtD
Lovastatin—Hepatic function abnormal—Doxorubicin—sarcoma	0.000377	0.00331	CcSEcCtD
Lovastatin—Anaphylactic shock—Mitoxantrone—sarcoma	0.000375	0.0033	CcSEcCtD
Lovastatin—Photosensitivity—Doxorubicin—sarcoma	0.000375	0.0033	CcSEcCtD
Lovastatin—Decreased appetite—Dactinomycin—sarcoma	0.000375	0.0033	CcSEcCtD
Lovastatin—Fatigue—Thiotepa—sarcoma	0.000374	0.00329	CcSEcCtD
Lovastatin—Dysgeusia—Etoposide—sarcoma	0.000374	0.00329	CcSEcCtD
Lovastatin—Infection—Mitoxantrone—sarcoma	0.000373	0.00328	CcSEcCtD
Lovastatin—Fatigue—Dactinomycin—sarcoma	0.000372	0.00327	CcSEcCtD
Lovastatin—Pain—Thiotepa—sarcoma	0.000371	0.00327	CcSEcCtD
Lovastatin—Constipation—Thiotepa—sarcoma	0.000371	0.00327	CcSEcCtD
Lovastatin—Back pain—Etoposide—sarcoma	0.00037	0.00325	CcSEcCtD
Lovastatin—ABCB1—myometrium—sarcoma	0.000369	0.00375	CbGeAlD
Lovastatin—Purpura—Epirubicin—sarcoma	0.000369	0.00325	CcSEcCtD
Lovastatin—Pain—Dactinomycin—sarcoma	0.000369	0.00324	CcSEcCtD
Lovastatin—Vascular purpura—Doxorubicin—sarcoma	0.000368	0.00324	CcSEcCtD
Lovastatin—Muscle spasms—Etoposide—sarcoma	0.000367	0.00323	CcSEcCtD
Lovastatin—Thrombocytopenia—Mitoxantrone—sarcoma	0.000367	0.00323	CcSEcCtD
Lovastatin—Anorexia—Vincristine—sarcoma	0.000367	0.00323	CcSEcCtD
Lovastatin—Hepatic failure—Doxorubicin—sarcoma	0.000366	0.00322	CcSEcCtD
Lovastatin—CYP2C8—testis—sarcoma	0.000363	0.00368	CbGeAlD
Lovastatin—Feeling abnormal—Thiotepa—sarcoma	0.000358	0.00315	CcSEcCtD
Lovastatin—Anorexia—Mitoxantrone—sarcoma	0.000357	0.00315	CcSEcCtD
Lovastatin—Pain in extremity—Epirubicin—sarcoma	0.000356	0.00313	CcSEcCtD
Lovastatin—ABCB1—embryo—sarcoma	0.000355	0.00361	CbGeAlD
Lovastatin—Feeling abnormal—Dactinomycin—sarcoma	0.000355	0.00313	CcSEcCtD
Lovastatin—Gastrointestinal pain—Thiotepa—sarcoma	0.000355	0.00313	CcSEcCtD
Lovastatin—Ill-defined disorder—Etoposide—sarcoma	0.000355	0.00312	CcSEcCtD
Lovastatin—Gastrointestinal pain—Dactinomycin—sarcoma	0.000352	0.0031	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Vincristine—sarcoma	0.000351	0.00309	CcSEcCtD
Lovastatin—ABCC2—lymph node—sarcoma	0.00035	0.00356	CbGeAlD
Lovastatin—Insomnia—Vincristine—sarcoma	0.000348	0.00307	CcSEcCtD
Lovastatin—Paraesthesia—Vincristine—sarcoma	0.000346	0.00304	CcSEcCtD
Lovastatin—Urticaria—Thiotepa—sarcoma	0.000345	0.00304	CcSEcCtD
Lovastatin—Malaise—Etoposide—sarcoma	0.000345	0.00303	CcSEcCtD
Lovastatin—Vertigo—Etoposide—sarcoma	0.000343	0.00302	CcSEcCtD
Lovastatin—Body temperature increased—Thiotepa—sarcoma	0.000343	0.00302	CcSEcCtD
Lovastatin—Abdominal pain—Thiotepa—sarcoma	0.000343	0.00302	CcSEcCtD
Lovastatin—CYP2C8—liver—sarcoma	0.000343	0.00348	CbGeAlD
Lovastatin—Leukopenia—Etoposide—sarcoma	0.000342	0.00301	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000342	0.00301	CcSEcCtD
Lovastatin—Purpura—Doxorubicin—sarcoma	0.000342	0.00301	CcSEcCtD
Lovastatin—Body temperature increased—Dactinomycin—sarcoma	0.000341	0.003	CcSEcCtD
Lovastatin—Abdominal pain—Dactinomycin—sarcoma	0.000341	0.003	CcSEcCtD
Lovastatin—Paraesthesia—Mitoxantrone—sarcoma	0.000337	0.00296	CcSEcCtD
Lovastatin—Decreased appetite—Vincristine—sarcoma	0.000335	0.00295	CcSEcCtD
Lovastatin—Dyspnoea—Mitoxantrone—sarcoma	0.000334	0.00294	CcSEcCtD
Lovastatin—ABCB1—seminal vesicle—sarcoma	0.000334	0.00339	CbGeAlD
Lovastatin—Fatigue—Vincristine—sarcoma	0.000332	0.00292	CcSEcCtD
Lovastatin—Dyspepsia—Mitoxantrone—sarcoma	0.00033	0.00291	CcSEcCtD
Lovastatin—Constipation—Vincristine—sarcoma	0.000329	0.0029	CcSEcCtD
Lovastatin—Pain—Vincristine—sarcoma	0.000329	0.0029	CcSEcCtD
Lovastatin—Pain in extremity—Doxorubicin—sarcoma	0.000329	0.0029	CcSEcCtD
Lovastatin—Decreased appetite—Mitoxantrone—sarcoma	0.000326	0.00287	CcSEcCtD
Lovastatin—Chest pain—Etoposide—sarcoma	0.000325	0.00286	CcSEcCtD
Lovastatin—Fatigue—Mitoxantrone—sarcoma	0.000323	0.00285	CcSEcCtD
Lovastatin—Discomfort—Etoposide—sarcoma	0.000321	0.00283	CcSEcCtD
Lovastatin—Pain—Mitoxantrone—sarcoma	0.000321	0.00282	CcSEcCtD
Lovastatin—Constipation—Mitoxantrone—sarcoma	0.000321	0.00282	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.00032	0.00282	CcSEcCtD
Lovastatin—Hypersensitivity—Thiotepa—sarcoma	0.00032	0.00282	CcSEcCtD
Lovastatin—Hypersensitivity—Dactinomycin—sarcoma	0.000318	0.00279	CcSEcCtD
Lovastatin—ABCB1—hematopoietic system—sarcoma	0.000317	0.00322	CbGeAlD
Lovastatin—Gastrointestinal pain—Vincristine—sarcoma	0.000315	0.00277	CcSEcCtD
Lovastatin—Confusional state—Etoposide—sarcoma	0.000315	0.00277	CcSEcCtD
Lovastatin—Anaphylactic shock—Etoposide—sarcoma	0.000312	0.00275	CcSEcCtD
Lovastatin—Asthenia—Thiotepa—sarcoma	0.000312	0.00274	CcSEcCtD
Lovastatin—Infection—Etoposide—sarcoma	0.00031	0.00273	CcSEcCtD
Lovastatin—CYP3A5—liver—sarcoma	0.000309	0.00314	CbGeAlD
Lovastatin—Asthenia—Dactinomycin—sarcoma	0.000309	0.00272	CcSEcCtD
Lovastatin—Feeling abnormal—Mitoxantrone—sarcoma	0.000309	0.00272	CcSEcCtD
Lovastatin—Influenza—Epirubicin—sarcoma	0.000307	0.00271	CcSEcCtD
Lovastatin—Pruritus—Thiotepa—sarcoma	0.000307	0.0027	CcSEcCtD
Lovastatin—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000307	0.0027	CcSEcCtD
Lovastatin—Thrombocytopenia—Etoposide—sarcoma	0.000305	0.00269	CcSEcCtD
Lovastatin—CYP2C9—liver—sarcoma	0.000304	0.00309	CbGeAlD
Lovastatin—Eosinophilia—Epirubicin—sarcoma	0.000304	0.00268	CcSEcCtD
Lovastatin—Abdominal pain—Vincristine—sarcoma	0.000304	0.00268	CcSEcCtD
Lovastatin—Body temperature increased—Vincristine—sarcoma	0.000304	0.00268	CcSEcCtD
Lovastatin—Pancreatitis—Epirubicin—sarcoma	0.000301	0.00265	CcSEcCtD
Lovastatin—Urticaria—Mitoxantrone—sarcoma	0.000298	0.00262	CcSEcCtD
Lovastatin—Anorexia—Etoposide—sarcoma	0.000297	0.00262	CcSEcCtD
Lovastatin—Diarrhoea—Thiotepa—sarcoma	0.000297	0.00261	CcSEcCtD
Lovastatin—Body temperature increased—Mitoxantrone—sarcoma	0.000296	0.00261	CcSEcCtD
Lovastatin—Abdominal pain—Mitoxantrone—sarcoma	0.000296	0.00261	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000296	0.00261	CcSEcCtD
Lovastatin—Diarrhoea—Dactinomycin—sarcoma	0.000295	0.0026	CcSEcCtD
Lovastatin—Dizziness—Thiotepa—sarcoma	0.000287	0.00253	CcSEcCtD
Lovastatin—Influenza—Doxorubicin—sarcoma	0.000284	0.0025	CcSEcCtD
Lovastatin—Hypersensitivity—Vincristine—sarcoma	0.000284	0.0025	CcSEcCtD
Lovastatin—Eosinophilia—Doxorubicin—sarcoma	0.000282	0.00248	CcSEcCtD
Lovastatin—Photosensitivity reaction—Epirubicin—sarcoma	0.000281	0.00247	CcSEcCtD
Lovastatin—Paraesthesia—Etoposide—sarcoma	0.00028	0.00247	CcSEcCtD
Lovastatin—Pancreatitis—Doxorubicin—sarcoma	0.000279	0.00245	CcSEcCtD
Lovastatin—Dyspnoea—Etoposide—sarcoma	0.000278	0.00245	CcSEcCtD
Lovastatin—ITGAL—Focal Adhesion—JUN—sarcoma	0.000278	0.00472	CbGpPWpGaD
Lovastatin—ITGAL—Extracellular matrix organization—MMP2—sarcoma	0.000276	0.0047	CbGpPWpGaD
Lovastatin—Hypersensitivity—Mitoxantrone—sarcoma	0.000276	0.00243	CcSEcCtD
Lovastatin—Asthenia—Vincristine—sarcoma	0.000276	0.00243	CcSEcCtD
Lovastatin—Vomiting—Thiotepa—sarcoma	0.000276	0.00243	CcSEcCtD
Lovastatin—ITGAL—Focal Adhesion—CTNNB1—sarcoma	0.000276	0.00468	CbGpPWpGaD
Lovastatin—Vomiting—Dactinomycin—sarcoma	0.000274	0.00241	CcSEcCtD
Lovastatin—Rash—Thiotepa—sarcoma	0.000274	0.00241	CcSEcCtD
Lovastatin—Dermatitis—Thiotepa—sarcoma	0.000274	0.00241	CcSEcCtD
Lovastatin—Headache—Thiotepa—sarcoma	0.000272	0.00239	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000272	0.00239	CcSEcCtD
Lovastatin—Rash—Dactinomycin—sarcoma	0.000272	0.00239	CcSEcCtD
Lovastatin—Decreased appetite—Etoposide—sarcoma	0.000271	0.00239	CcSEcCtD
Lovastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000271	0.0046	CbGpPWpGaD
Lovastatin—Asthenia—Mitoxantrone—sarcoma	0.000269	0.00237	CcSEcCtD
Lovastatin—Fatigue—Etoposide—sarcoma	0.000269	0.00237	CcSEcCtD
Lovastatin—Neuropathy peripheral—Epirubicin—sarcoma	0.000269	0.00237	CcSEcCtD
Lovastatin—Constipation—Etoposide—sarcoma	0.000267	0.00235	CcSEcCtD
Lovastatin—Pain—Etoposide—sarcoma	0.000267	0.00235	CcSEcCtD
Lovastatin—Urinary tract infection—Epirubicin—sarcoma	0.000266	0.00235	CcSEcCtD
Lovastatin—Diarrhoea—Vincristine—sarcoma	0.000263	0.00232	CcSEcCtD
Lovastatin—Photosensitivity reaction—Doxorubicin—sarcoma	0.00026	0.00229	CcSEcCtD
Lovastatin—Nausea—Thiotepa—sarcoma	0.000258	0.00227	CcSEcCtD
Lovastatin—Sinusitis—Epirubicin—sarcoma	0.000257	0.00226	CcSEcCtD
Lovastatin—Feeling abnormal—Etoposide—sarcoma	0.000257	0.00226	CcSEcCtD
Lovastatin—Diarrhoea—Mitoxantrone—sarcoma	0.000257	0.00226	CcSEcCtD
Lovastatin—Nausea—Dactinomycin—sarcoma	0.000256	0.00225	CcSEcCtD
Lovastatin—Gastrointestinal pain—Etoposide—sarcoma	0.000255	0.00224	CcSEcCtD
Lovastatin—Dizziness—Vincristine—sarcoma	0.000255	0.00224	CcSEcCtD
Lovastatin—ITGAL—Immune System—CD34—sarcoma	0.000254	0.00432	CbGpPWpGaD
Lovastatin—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000251	0.00221	CcSEcCtD
Lovastatin—ITGAL—Focal Adhesion—SRC—sarcoma	0.000249	0.00423	CbGpPWpGaD
Lovastatin—Neuropathy peripheral—Doxorubicin—sarcoma	0.000249	0.00219	CcSEcCtD
Lovastatin—Urticaria—Etoposide—sarcoma	0.000248	0.00218	CcSEcCtD
Lovastatin—Abdominal pain—Etoposide—sarcoma	0.000247	0.00217	CcSEcCtD
Lovastatin—Body temperature increased—Etoposide—sarcoma	0.000247	0.00217	CcSEcCtD
Lovastatin—Urinary tract infection—Doxorubicin—sarcoma	0.000247	0.00217	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.000246	0.00418	CbGpPWpGaD
Lovastatin—Hepatitis—Epirubicin—sarcoma	0.000246	0.00217	CcSEcCtD
Lovastatin—Vomiting—Vincristine—sarcoma	0.000245	0.00215	CcSEcCtD
Lovastatin—CYP2C19—Melatonin metabolism and effects—FOXO1—sarcoma	0.000244	0.00414	CbGpPWpGaD
Lovastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000243	0.00413	CbGpPWpGaD
Lovastatin—Rash—Vincristine—sarcoma	0.000243	0.00214	CcSEcCtD
Lovastatin—ITGAL—Focal Adhesion—VEGFA—sarcoma	0.000243	0.00412	CbGpPWpGaD
Lovastatin—Dermatitis—Vincristine—sarcoma	0.000243	0.00213	CcSEcCtD
Lovastatin—CYP2D6—testis—sarcoma	0.000242	0.00245	CbGeAlD
Lovastatin—Headache—Vincristine—sarcoma	0.000241	0.00212	CcSEcCtD
Lovastatin—ABCB1—uterus—sarcoma	0.00024	0.00243	CbGeAlD
Lovastatin—Vomiting—Mitoxantrone—sarcoma	0.000238	0.0021	CcSEcCtD
Lovastatin—Sinusitis—Doxorubicin—sarcoma	0.000238	0.00209	CcSEcCtD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000236	0.00402	CbGpPWpGaD
Lovastatin—Rash—Mitoxantrone—sarcoma	0.000236	0.00208	CcSEcCtD
Lovastatin—Dermatitis—Mitoxantrone—sarcoma	0.000236	0.00208	CcSEcCtD
Lovastatin—Headache—Mitoxantrone—sarcoma	0.000235	0.00207	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.000235	0.00399	CbGpPWpGaD
Lovastatin—Erythema multiforme—Epirubicin—sarcoma	0.000233	0.00205	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—CREB1—sarcoma	0.000233	0.00395	CbGpPWpGaD
Lovastatin—CYP3A4—liver—sarcoma	0.000232	0.00236	CbGeAlD
Lovastatin—Hypersensitivity—Etoposide—sarcoma	0.00023	0.00202	CcSEcCtD
Lovastatin—Nausea—Vincristine—sarcoma	0.000229	0.00201	CcSEcCtD
Lovastatin—CYP2D6—liver—sarcoma	0.000228	0.00232	CbGeAlD
Lovastatin—Flushing—Epirubicin—sarcoma	0.000228	0.00201	CcSEcCtD
Lovastatin—Hepatitis—Doxorubicin—sarcoma	0.000228	0.002	CcSEcCtD
Lovastatin—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000225	0.00383	CbGpPWpGaD
Lovastatin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000224	0.00381	CbGpPWpGaD
Lovastatin—CYP2D6—Melatonin metabolism and effects—FOXO1—sarcoma	0.000224	0.00381	CbGpPWpGaD
Lovastatin—Asthenia—Etoposide—sarcoma	0.000224	0.00197	CcSEcCtD
Lovastatin—ABCB1—lymphoid tissue—sarcoma	0.000223	0.00227	CbGeAlD
Lovastatin—Nausea—Mitoxantrone—sarcoma	0.000223	0.00196	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	0.000221	0.00375	CbGpPWpGaD
Lovastatin—Chills—Epirubicin—sarcoma	0.000221	0.00194	CcSEcCtD
Lovastatin—Pruritus—Etoposide—sarcoma	0.000221	0.00194	CcSEcCtD
Lovastatin—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.00022	0.00374	CbGpPWpGaD
Lovastatin—ITGAL—Focal Adhesion—EGFR—sarcoma	0.000218	0.00371	CbGpPWpGaD
Lovastatin—Alopecia—Epirubicin—sarcoma	0.000217	0.00191	CcSEcCtD
Lovastatin—Erythema multiforme—Doxorubicin—sarcoma	0.000215	0.00189	CcSEcCtD
Lovastatin—Diarrhoea—Etoposide—sarcoma	0.000213	0.00188	CcSEcCtD
Lovastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000213	0.00362	CbGpPWpGaD
Lovastatin—HDAC2—Notch Signaling Pathway—CCND1—sarcoma	0.000212	0.00361	CbGpPWpGaD
Lovastatin—Flushing—Doxorubicin—sarcoma	0.000211	0.00186	CcSEcCtD
Lovastatin—Flatulence—Epirubicin—sarcoma	0.000211	0.00186	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—FOXO1—sarcoma	0.00021	0.00357	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—PDGFRB—sarcoma	0.00021	0.00357	CbGpPWpGaD
Lovastatin—HDAC2—NOTCH1 Intracellular Domain Regulates Transcription—MYC—sarcoma	0.00021	0.00356	CbGpPWpGaD
Lovastatin—Dysgeusia—Epirubicin—sarcoma	0.00021	0.00185	CcSEcCtD
Lovastatin—Back pain—Epirubicin—sarcoma	0.000207	0.00182	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—PDGFRA—sarcoma	0.000207	0.00351	CbGpPWpGaD
Lovastatin—Dizziness—Etoposide—sarcoma	0.000206	0.00182	CcSEcCtD
Lovastatin—Muscle spasms—Epirubicin—sarcoma	0.000206	0.00181	CcSEcCtD
Lovastatin—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000206	0.00349	CbGpPWpGaD
Lovastatin—Chills—Doxorubicin—sarcoma	0.000204	0.0018	CcSEcCtD
Lovastatin—ABCB1—bone marrow—sarcoma	0.000203	0.00206	CbGeAlD
Lovastatin—Vision blurred—Epirubicin—sarcoma	0.000202	0.00178	CcSEcCtD
Lovastatin—Alopecia—Doxorubicin—sarcoma	0.000201	0.00177	CcSEcCtD
Lovastatin—HDAC2—Regulation of Telomerase—IL2—sarcoma	0.0002	0.00339	CbGpPWpGaD
Lovastatin—Ill-defined disorder—Epirubicin—sarcoma	0.000199	0.00175	CcSEcCtD
Lovastatin—Vomiting—Etoposide—sarcoma	0.000198	0.00175	CcSEcCtD
Lovastatin—Rash—Etoposide—sarcoma	0.000197	0.00173	CcSEcCtD
Lovastatin—Dermatitis—Etoposide—sarcoma	0.000196	0.00173	CcSEcCtD
Lovastatin—Headache—Etoposide—sarcoma	0.000195	0.00172	CcSEcCtD
Lovastatin—Flatulence—Doxorubicin—sarcoma	0.000195	0.00172	CcSEcCtD
Lovastatin—HDAC2—Regulation of Telomerase—CCND1—sarcoma	0.000195	0.00331	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of Telomerase—JUN—sarcoma	0.000194	0.0033	CbGpPWpGaD
Lovastatin—Dysgeusia—Doxorubicin—sarcoma	0.000194	0.00171	CcSEcCtD
Lovastatin—Malaise—Epirubicin—sarcoma	0.000193	0.0017	CcSEcCtD
Lovastatin—Vertigo—Epirubicin—sarcoma	0.000192	0.00169	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—MDM2—sarcoma	0.000192	0.00327	CbGpPWpGaD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000192	0.00327	CbGpPWpGaD
Lovastatin—Leukopenia—Epirubicin—sarcoma	0.000192	0.00169	CcSEcCtD
Lovastatin—Back pain—Doxorubicin—sarcoma	0.000192	0.00169	CcSEcCtD
Lovastatin—Muscle spasms—Doxorubicin—sarcoma	0.000191	0.00168	CcSEcCtD
Lovastatin—HDAC2—Notch Signaling Pathway—SRC—sarcoma	0.00019	0.00323	CbGpPWpGaD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000187	0.00318	CbGpPWpGaD
Lovastatin—Vision blurred—Doxorubicin—sarcoma	0.000187	0.00164	CcSEcCtD
Lovastatin—Nausea—Etoposide—sarcoma	0.000185	0.00163	CcSEcCtD
Lovastatin—HDAC2—Signaling by NOTCH—CREB1—sarcoma	0.000185	0.00315	CbGpPWpGaD
Lovastatin—Ill-defined disorder—Doxorubicin—sarcoma	0.000184	0.00162	CcSEcCtD
Lovastatin—ITGAL—Immune System—PTPRC—sarcoma	0.000184	0.00312	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—TEK—sarcoma	0.000183	0.0031	CbGpPWpGaD
Lovastatin—HDAC2—Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants—MYC—sarcoma	0.000182	0.0031	CbGpPWpGaD
Lovastatin—Arthralgia—Epirubicin—sarcoma	0.000182	0.00161	CcSEcCtD
Lovastatin—Myalgia—Epirubicin—sarcoma	0.000182	0.00161	CcSEcCtD
Lovastatin—Chest pain—Epirubicin—sarcoma	0.000182	0.00161	CcSEcCtD
Lovastatin—Anxiety—Epirubicin—sarcoma	0.000182	0.0016	CcSEcCtD
Lovastatin—Discomfort—Epirubicin—sarcoma	0.00018	0.00159	CcSEcCtD
Lovastatin—ITGAL—Immune System—PLCG1—sarcoma	0.00018	0.00305	CbGpPWpGaD
Lovastatin—Malaise—Doxorubicin—sarcoma	0.000179	0.00157	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000179	0.00303	CbGpPWpGaD
Lovastatin—Dry mouth—Epirubicin—sarcoma	0.000178	0.00157	CcSEcCtD
Lovastatin—Vertigo—Doxorubicin—sarcoma	0.000178	0.00157	CcSEcCtD
Lovastatin—Leukopenia—Doxorubicin—sarcoma	0.000177	0.00156	CcSEcCtD
Lovastatin—Confusional state—Epirubicin—sarcoma	0.000176	0.00155	CcSEcCtD
Lovastatin—ITGAL—Focal Adhesion—HRAS—sarcoma	0.000175	0.00298	CbGpPWpGaD
Lovastatin—Anaphylactic shock—Epirubicin—sarcoma	0.000175	0.00154	CcSEcCtD
Lovastatin—ABCB1—testis—sarcoma	0.000174	0.00176	CbGeAlD
Lovastatin—Infection—Epirubicin—sarcoma	0.000174	0.00153	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—IL2—sarcoma	0.000172	0.00292	CbGpPWpGaD
Lovastatin—Thrombocytopenia—Epirubicin—sarcoma	0.000171	0.00151	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.000171	0.0029	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—ATF1—sarcoma	0.000171	0.0029	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.000171	0.0029	CbGpPWpGaD
Lovastatin—HDAC2—Notch Signaling Pathway—MYC—sarcoma	0.00017	0.00289	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.000169	0.00288	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	0.000169	0.00287	CbGpPWpGaD
Lovastatin—Chest pain—Doxorubicin—sarcoma	0.000169	0.00149	CcSEcCtD
Lovastatin—Arthralgia—Doxorubicin—sarcoma	0.000169	0.00149	CcSEcCtD
Lovastatin—Myalgia—Doxorubicin—sarcoma	0.000169	0.00149	CcSEcCtD
Lovastatin—Anxiety—Doxorubicin—sarcoma	0.000168	0.00148	CcSEcCtD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000168	0.00285	CbGpPWpGaD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—JUN—sarcoma	0.000167	0.00284	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—ANGPT2—sarcoma	0.000167	0.00284	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000167	0.00284	CbGpPWpGaD
Lovastatin—Discomfort—Doxorubicin—sarcoma	0.000167	0.00147	CcSEcCtD
Lovastatin—Anorexia—Epirubicin—sarcoma	0.000167	0.00147	CcSEcCtD
Lovastatin—HDAC2—Signaling by NGF—PLCG1—sarcoma	0.000166	0.00283	CbGpPWpGaD
Lovastatin—Dry mouth—Doxorubicin—sarcoma	0.000165	0.00145	CcSEcCtD
Lovastatin—ABCB1—liver—sarcoma	0.000164	0.00167	CbGeAlD
Lovastatin—Confusional state—Doxorubicin—sarcoma	0.000163	0.00144	CcSEcCtD
Lovastatin—Anaphylactic shock—Doxorubicin—sarcoma	0.000162	0.00142	CcSEcCtD
Lovastatin—HDAC2—Cell Cycle—MDM2—sarcoma	0.000162	0.00274	CbGpPWpGaD
Lovastatin—Infection—Doxorubicin—sarcoma	0.000161	0.00141	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—KIT—sarcoma	0.00016	0.00272	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000159	0.0014	CcSEcCtD
Lovastatin—HMGCR—AMPK Signaling—TP53—sarcoma	0.000159	0.00269	CbGpPWpGaD
Lovastatin—Thrombocytopenia—Doxorubicin—sarcoma	0.000158	0.00139	CcSEcCtD
Lovastatin—Insomnia—Epirubicin—sarcoma	0.000158	0.00139	CcSEcCtD
Lovastatin—HDAC2—Signaling by NGF—ATF1—sarcoma	0.000158	0.00268	CbGpPWpGaD
Lovastatin—Paraesthesia—Epirubicin—sarcoma	0.000157	0.00138	CcSEcCtD
Lovastatin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000156	0.00265	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of Telomerase—MYC—sarcoma	0.000156	0.00265	CbGpPWpGaD
Lovastatin—Dyspnoea—Epirubicin—sarcoma	0.000156	0.00137	CcSEcCtD
Lovastatin—Anorexia—Doxorubicin—sarcoma	0.000154	0.00136	CcSEcCtD
Lovastatin—Dyspepsia—Epirubicin—sarcoma	0.000154	0.00135	CcSEcCtD
Lovastatin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000154	0.00261	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of Telomerase—EGFR—sarcoma	0.000153	0.00259	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—CREB1—sarcoma	0.000153	0.00259	CbGpPWpGaD
Lovastatin—Decreased appetite—Epirubicin—sarcoma	0.000152	0.00134	CcSEcCtD
Lovastatin—HDAC2—FBXW7 Mutants and NOTCH1 in Cancer—MYC—sarcoma	0.000151	0.00256	CbGpPWpGaD
Lovastatin—Fatigue—Epirubicin—sarcoma	0.000151	0.00133	CcSEcCtD
Lovastatin—Constipation—Epirubicin—sarcoma	0.00015	0.00132	CcSEcCtD
Lovastatin—Pain—Epirubicin—sarcoma	0.00015	0.00132	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000148	0.00251	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000147	0.0013	CcSEcCtD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000147	0.0025	CbGpPWpGaD
Lovastatin—Insomnia—Doxorubicin—sarcoma	0.000146	0.00129	CcSEcCtD
Lovastatin—Paraesthesia—Doxorubicin—sarcoma	0.000145	0.00128	CcSEcCtD
Lovastatin—Dyspnoea—Doxorubicin—sarcoma	0.000144	0.00127	CcSEcCtD
Lovastatin—Feeling abnormal—Epirubicin—sarcoma	0.000144	0.00127	CcSEcCtD
Lovastatin—Gastrointestinal pain—Epirubicin—sarcoma	0.000143	0.00126	CcSEcCtD
Lovastatin—Dyspepsia—Doxorubicin—sarcoma	0.000142	0.00125	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—MMP2—sarcoma	0.000141	0.0024	CbGpPWpGaD
Lovastatin—Decreased appetite—Doxorubicin—sarcoma	0.000141	0.00124	CcSEcCtD
Lovastatin—HDAC2—Neural Crest Differentiation—CTNNB1—sarcoma	0.000141	0.00239	CbGpPWpGaD
Lovastatin—Fatigue—Doxorubicin—sarcoma	0.000139	0.00123	CcSEcCtD
Lovastatin—Urticaria—Epirubicin—sarcoma	0.000139	0.00122	CcSEcCtD
Lovastatin—Pain—Doxorubicin—sarcoma	0.000138	0.00122	CcSEcCtD
Lovastatin—Constipation—Doxorubicin—sarcoma	0.000138	0.00122	CcSEcCtD
Lovastatin—Body temperature increased—Epirubicin—sarcoma	0.000138	0.00122	CcSEcCtD
Lovastatin—Abdominal pain—Epirubicin—sarcoma	0.000138	0.00122	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	0.000137	0.00233	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	0.000136	0.00231	CbGpPWpGaD
Lovastatin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000136	0.0023	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—VEGFC—sarcoma	0.000134	0.00228	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NOTCH—CCND1—sarcoma	0.000134	0.00227	CbGpPWpGaD
Lovastatin—Feeling abnormal—Doxorubicin—sarcoma	0.000133	0.00117	CcSEcCtD
Lovastatin—HDAC2—Signaling by NOTCH—JUN—sarcoma	0.000133	0.00226	CbGpPWpGaD
Lovastatin—Gastrointestinal pain—Doxorubicin—sarcoma	0.000132	0.00116	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—IL2—sarcoma	0.00013	0.00222	CbGpPWpGaD
Lovastatin—Hypersensitivity—Epirubicin—sarcoma	0.000129	0.00113	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000129	0.00219	CbGpPWpGaD
Lovastatin—Urticaria—Doxorubicin—sarcoma	0.000129	0.00113	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000128	0.00218	CbGpPWpGaD
Lovastatin—Abdominal pain—Doxorubicin—sarcoma	0.000128	0.00113	CcSEcCtD
Lovastatin—Body temperature increased—Doxorubicin—sarcoma	0.000128	0.00113	CcSEcCtD
Lovastatin—ITGAL—Immune System—FOXO1—sarcoma	0.000128	0.00217	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000127	0.00216	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—PDGFRB—sarcoma	0.000127	0.00216	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—MDM2—sarcoma	0.000126	0.00214	CbGpPWpGaD
Lovastatin—ABCB1—lymph node—sarcoma	0.000126	0.00128	CbGeAlD
Lovastatin—HDAC2—Gene Expression—FUS—sarcoma	0.000126	0.00214	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—MDM2—sarcoma	0.000125	0.00213	CbGpPWpGaD
Lovastatin—Asthenia—Epirubicin—sarcoma	0.000125	0.0011	CcSEcCtD
Lovastatin—ITGAL—Immune System—PDGFRA—sarcoma	0.000125	0.00213	CbGpPWpGaD
Lovastatin—Pruritus—Epirubicin—sarcoma	0.000124	0.00109	CcSEcCtD
Lovastatin—Diarrhoea—Epirubicin—sarcoma	0.00012	0.00105	CcSEcCtD
Lovastatin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	0.000119	0.00203	CbGpPWpGaD
Lovastatin—Hypersensitivity—Doxorubicin—sarcoma	0.000119	0.00105	CcSEcCtD
Lovastatin—HDAC2—Signaling by NGF—FOXO1—sarcoma	0.000118	0.002	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—PDGFRB—sarcoma	0.000118	0.002	CbGpPWpGaD
Lovastatin—Asthenia—Doxorubicin—sarcoma	0.000116	0.00102	CcSEcCtD
Lovastatin—HDAC2—Signaling by NGF—PDGFRA—sarcoma	0.000116	0.00197	CbGpPWpGaD
Lovastatin—Dizziness—Epirubicin—sarcoma	0.000116	0.00102	CcSEcCtD
Lovastatin—Pruritus—Doxorubicin—sarcoma	0.000114	0.00101	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—SRC—sarcoma	0.000114	0.00193	CbGpPWpGaD
Lovastatin—HDAC2—Neural Crest Differentiation—MYC—sarcoma	0.000114	0.00193	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—CREB1—sarcoma	0.000114	0.00193	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000112	0.0019	CbGpPWpGaD
Lovastatin—Vomiting—Epirubicin—sarcoma	0.000111	0.000978	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—VEGFA—sarcoma	0.000111	0.00188	CbGpPWpGaD
Lovastatin—Diarrhoea—Doxorubicin—sarcoma	0.000111	0.000974	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—TP53—sarcoma	0.00011	0.00188	CbGpPWpGaD
Lovastatin—Rash—Epirubicin—sarcoma	0.00011	0.00097	CcSEcCtD
Lovastatin—Dermatitis—Epirubicin—sarcoma	0.00011	0.000969	CcSEcCtD
Lovastatin—Headache—Epirubicin—sarcoma	0.00011	0.000964	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—NRAS—sarcoma	0.00011	0.00186	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—JUN—sarcoma	0.000109	0.00185	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NOTCH—MYC—sarcoma	0.000107	0.00182	CbGpPWpGaD
Lovastatin—Dizziness—Doxorubicin—sarcoma	0.000107	0.000942	CcSEcCtD
Lovastatin—HDAC2—Hemostasis—PLCG1—sarcoma	0.000105	0.00179	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—PDGFRA—sarcoma	0.000105	0.00178	CbGpPWpGaD
Lovastatin—Nausea—Epirubicin—sarcoma	0.000104	0.000914	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000103	0.00175	CbGpPWpGaD
Lovastatin—Vomiting—Doxorubicin—sarcoma	0.000103	0.000905	CcSEcCtD
Lovastatin—Rash—Doxorubicin—sarcoma	0.000102	0.000898	CcSEcCtD
Lovastatin—Dermatitis—Doxorubicin—sarcoma	0.000102	0.000897	CcSEcCtD
Lovastatin—Headache—Doxorubicin—sarcoma	0.000101	0.000892	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000101	0.00171	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—SRC—sarcoma	9.84e-05	0.00167	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	9.76e-05	0.00166	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—KIT—sarcoma	9.72e-05	0.00165	CbGpPWpGaD
Lovastatin—Nausea—Doxorubicin—sarcoma	9.61e-05	0.000846	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—KRAS—sarcoma	9.54e-05	0.00162	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—NRAS—sarcoma	9.47e-05	0.00161	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—KRAS—sarcoma	9.43e-05	0.0016	CbGpPWpGaD
Lovastatin—HDAC2—Cell Cycle—TP53—sarcoma	9.27e-05	0.00157	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—CREB1—sarcoma	9.25e-05	0.00157	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—KIT—sarcoma	9e-05	0.00153	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	8.94e-05	0.00152	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NOTCH—TP53—sarcoma	8.79e-05	0.00149	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—EGFR—sarcoma	8.63e-05	0.00146	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—EGFR—sarcoma	8.57e-05	0.00146	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—CREB1—sarcoma	8.56e-05	0.00145	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—TP53—sarcoma	8.48e-05	0.00144	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—TP53—sarcoma	8.38e-05	0.00142	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—JUN—sarcoma	8.17e-05	0.00139	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—KRAS—sarcoma	8.15e-05	0.00138	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—HRAS—sarcoma	8.01e-05	0.00136	CbGpPWpGaD
Lovastatin—HDAC2—Disease—TLE1—sarcoma	7.7e-05	0.00131	CbGpPWpGaD
Lovastatin—HDAC2—Chromatin modifying enzymes—CCND1—sarcoma	7.7e-05	0.00131	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—MDM2—sarcoma	7.66e-05	0.0013	CbGpPWpGaD
Lovastatin—HDAC2—Factors involved in megakaryocyte development and platelet production—TP53—sarcoma	7.37e-05	0.00125	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—TP53—sarcoma	7.2e-05	0.00122	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—MDM2—sarcoma	7.08e-05	0.0012	CbGpPWpGaD
Lovastatin—HDAC2—Disease—NPM1—sarcoma	6.94e-05	0.00118	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—HRAS—sarcoma	6.93e-05	0.00118	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—IL2—sarcoma	6.84e-05	0.00116	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—JUN—sarcoma	6.66e-05	0.00113	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—CTNNB1—sarcoma	6.6e-05	0.00112	CbGpPWpGaD
Lovastatin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	6.56e-05	0.00111	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	6.43e-05	0.00109	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—ENO2—sarcoma	6.3e-05	0.00107	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—HBA1—sarcoma	6.26e-05	0.00106	CbGpPWpGaD
Lovastatin—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	6.09e-05	0.00103	CbGpPWpGaD
Lovastatin—HDAC2—Disease—ENO2—sarcoma	6.01e-05	0.00102	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—SRC—sarcoma	5.97e-05	0.00101	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—NRAS—sarcoma	5.74e-05	0.000975	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—IL2—sarcoma	5.73e-05	0.000972	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	5.62e-05	0.000954	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—SRC—sarcoma	5.52e-05	0.000938	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TLE1—sarcoma	5.39e-05	0.000915	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—TP53—sarcoma	5.39e-05	0.000915	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PLCG1—sarcoma	5.35e-05	0.000908	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—NRAS—sarcoma	5.31e-05	0.000902	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—EGFR—sarcoma	5.23e-05	0.000889	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	5.18e-05	0.00088	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—ENO2—sarcoma	5.14e-05	0.000872	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—HBA1—sarcoma	5.1e-05	0.000867	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PLCG1—sarcoma	5.1e-05	0.000867	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—KRAS—sarcoma	4.94e-05	0.000839	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CXCR4—sarcoma	4.9e-05	0.000833	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—VEGFA—sarcoma	4.87e-05	0.000826	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—EGFR—sarcoma	4.84e-05	0.000822	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—KRAS—sarcoma	4.57e-05	0.000777	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—VEGFC—sarcoma	4.55e-05	0.000772	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—ENO2—sarcoma	4.37e-05	0.000742	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PLCG1—sarcoma	4.36e-05	0.00074	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—HBA1—sarcoma	4.34e-05	0.000737	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—HRAS—sarcoma	4.2e-05	0.000714	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—IL2—sarcoma	4.01e-05	0.000681	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—HRAS—sarcoma	3.89e-05	0.00066	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.82e-05	0.000649	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—ENO2—sarcoma	3.8e-05	0.000646	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—HBA1—sarcoma	3.78e-05	0.000642	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PLCG1—sarcoma	3.71e-05	0.000629	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—FLT1—sarcoma	3.64e-05	0.000617	CbGpPWpGaD
Lovastatin—HDAC2—Disease—FOXO1—sarcoma	3.62e-05	0.000615	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PDGFRB—sarcoma	3.61e-05	0.000614	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PLCG1—sarcoma	3.57e-05	0.000607	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PDGFRA—sarcoma	3.56e-05	0.000604	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—ENO2—sarcoma	3.55e-05	0.000603	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—HBA1—sarcoma	3.53e-05	0.000599	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—SRC—sarcoma	3.5e-05	0.000594	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CXCR4—sarcoma	3.43e-05	0.000583	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—VEGFA—sarcoma	3.41e-05	0.000579	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—ATF1—sarcoma	3.39e-05	0.000577	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—NRAS—sarcoma	3.37e-05	0.000572	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—ENO2—sarcoma	3.25e-05	0.000552	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—HBA1—sarcoma	3.23e-05	0.000549	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PLCG1—sarcoma	3.23e-05	0.000548	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.16e-05	0.000537	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PLCG1—sarcoma	3.01e-05	0.000511	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—ENO2—sarcoma	2.98e-05	0.000507	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—HBA1—sarcoma	2.97e-05	0.000504	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—KRAS—sarcoma	2.9e-05	0.000492	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PLCG1—sarcoma	2.76e-05	0.000469	CbGpPWpGaD
Lovastatin—HDAC2—Disease—KIT—sarcoma	2.76e-05	0.000469	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.75e-05	0.000468	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.75e-05	0.000467	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.73e-05	0.000463	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IGF1R—sarcoma	2.66e-05	0.000452	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CREB1—sarcoma	2.63e-05	0.000446	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—TP53—sarcoma	2.58e-05	0.000437	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—FOXO1—sarcoma	2.54e-05	0.000431	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PLCG1—sarcoma	2.53e-05	0.00043	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PDGFRB—sarcoma	2.53e-05	0.00043	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PDGFRA—sarcoma	2.49e-05	0.000423	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.47e-05	0.000419	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—HRAS—sarcoma	2.46e-05	0.000418	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.4e-05	0.000408	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.21e-05	0.000375	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MDM2—sarcoma	2.17e-05	0.000369	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.16e-05	0.000367	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—ENO2—sarcoma	2.16e-05	0.000366	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—HBA1—sarcoma	2.14e-05	0.000364	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KDR—sarcoma	2.1e-05	0.000356	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.04e-05	0.000347	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KIT—sarcoma	1.93e-05	0.000328	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CTNNB1—sarcoma	1.87e-05	0.000318	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—ENO2—sarcoma	1.87e-05	0.000317	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—HBA1—sarcoma	1.86e-05	0.000315	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CREB1—sarcoma	1.84e-05	0.000312	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PLCG1—sarcoma	1.83e-05	0.000311	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.81e-05	0.000308	CbGpPWpGaD
Lovastatin—HDAC2—Disease—SRC—sarcoma	1.69e-05	0.000288	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—ENO2—sarcoma	1.67e-05	0.000283	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—HBA1—sarcoma	1.66e-05	0.000281	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—MYC—sarcoma	1.64e-05	0.000278	CbGpPWpGaD
Lovastatin—HDAC2—Disease—NRAS—sarcoma	1.63e-05	0.000277	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—ENO2—sarcoma	1.63e-05	0.000276	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—HBA1—sarcoma	1.62e-05	0.000275	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PLCG1—sarcoma	1.59e-05	0.000269	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—ENO2—sarcoma	1.53e-05	0.000261	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—HBA1—sarcoma	1.52e-05	0.000259	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MDM2—sarcoma	1.52e-05	0.000258	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—ENO2—sarcoma	1.52e-05	0.000258	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MYC—sarcoma	1.52e-05	0.000258	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—HBA1—sarcoma	1.51e-05	0.000257	CbGpPWpGaD
Lovastatin—HDAC2—Disease—EGFR—sarcoma	1.48e-05	0.000252	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PLCG1—sarcoma	1.42e-05	0.00024	CbGpPWpGaD
Lovastatin—HDAC2—Disease—KRAS—sarcoma	1.4e-05	0.000238	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PLCG1—sarcoma	1.38e-05	0.000235	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IL2—sarcoma	1.36e-05	0.000231	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CCND1—sarcoma	1.33e-05	0.000225	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—JUN—sarcoma	1.32e-05	0.000225	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CTNNB1—sarcoma	1.31e-05	0.000223	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PLCG1—sarcoma	1.3e-05	0.000221	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PLCG1—sarcoma	1.29e-05	0.000219	CbGpPWpGaD
Lovastatin—HDAC2—Disease—HRAS—sarcoma	1.19e-05	0.000202	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—SRC—sarcoma	1.19e-05	0.000201	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—VEGFA—sarcoma	1.16e-05	0.000196	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—NRAS—sarcoma	1.14e-05	0.000194	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MYC—sarcoma	1.06e-05	0.000181	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—EGFR—sarcoma	1.04e-05	0.000177	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—ENO2—sarcoma	1e-05	0.00017	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—HBA1—sarcoma	9.97e-06	0.000169	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KRAS—sarcoma	9.82e-06	0.000167	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TP53—sarcoma	8.73e-06	0.000148	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PLCG1—sarcoma	8.51e-06	0.000145	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—HRAS—sarcoma	8.35e-06	0.000142	CbGpPWpGaD
